EN DE

DC Healthcare Holdings (0283) Fair Value & Analysis

Healthcare · MY · Market cap 99.6M MYR

DH DC Healthcare Holdings 0283 · KLSE
Price0.1100 MYR
Fair Value0.0300 MYR
Upside-72.7%
Quality49/100
Watch DC Healthcare Holdings for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Thin margins · 1.3% net margin
Low debt · generates free cash flow
Mixed vs. peers (5/12)
Narrow moat 29/100
Evidence: High Range 0.0300 MYR – 0.0500 MYR Share as image

Fair value as of: Jul 12, 2026

From 22 valuation models · updated 29 days ago

Share price +10.0% over the past month.

Below-average quality, and screening another 73% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (0.0500 MYR). The favourable scenario is already priced in.
  • Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (3 years)

0.5300 MYR 0.0950 MYR Fair Value 0.0300 MYR Jul 2023 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.

How to read this chart

37‑month range 0.0950 MYR – 0.5300 MYR · fair‑value band 0.0300 MYR – 0.0500 MYR · the 0.1100 MYR price screens above the 0.0300 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 12, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

DC Healthcare Holdings (0283) currently trades at 0.1100 MYR, while our model-based Fair Value estimate is 0.0300 MYR, implying the stock looks roughly 72.7% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, DC Healthcare Holdings generated revenue of 90.5M MYR at a net margin of 1.3%. Revenue grew 19.3% year over year. It earns a return on equity of 2.6%. Net debt stands at 3.1M MYR. Fundamentals as of Jul 12, 2026

Our scenario range runs from 0.0300 MYR (bear case) to 0.0500 MYR (bull case); at 0.1100 MYR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 39% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -73%, 0283 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (0.0100 MYR to 0.2400 MYR). Read the values as a conservative anchor, not as a price target.
Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 0.0100 MYR 0.0100 MYR 0.0200 MYR 80
Residual Income 0.0300 MYR 0.0200 MYR 0.0100 MYR 76
ROIC Compounder 0.0200 MYR 0.0200 MYR 0.0200 MYR 72
All 22 models by family
DCF Models
FCF DCF 0.0100 MYR 0.0100 MYR 0.0200 MYR 38
5Y Revenue Exit 0.0200 MYR 0.0500 MYR 0.1000 MYR 39
5Y EBITDA Exit 0.1200 MYR 0.2300 MYR 0.4700 MYR 41
5Y P/E Exit 0.0100 MYR 0.0100 MYR 38
10Y Revenue Exit 0.0200 MYR 0.0500 MYR 0.0700 MYR 36
10Y EBITDA Exit 0.0800 MYR 0.2200 MYR 0.4800 MYR 37
10Y P/E Exit 0.0100 MYR 0.0100 MYR 0.0200 MYR 35
Earnings-Based
Graham-Dodd 0.0100 MYR 0.0100 MYR 54
Lynch FV 0.0100 MYR 0.0100 MYR 0.0100 MYR 50
PEG = 1.0 0.0100 MYR 0.0100 MYR 0.0100 MYR 46
EPV 0.0200 MYR 0.0200 MYR 0.0200 MYR 59
Dividend Discount
Gordon GGM 0.0200 MYR 0.0400 MYR 0.0500 MYR 70
DDM Multi-Stage 0.0200 MYR 0.0300 MYR 0.0400 MYR 61
Multiples
P/E Multiple 0.0100 MYR 63
EV/EBIT 0.0400 MYR 0.0600 MYR 0.0700 MYR 53
EV/EBITDA 0.1800 MYR 0.2400 MYR 0.3000 MYR 54
EV/Revenue 0.0300 MYR 0.0500 MYR 0.0600 MYR 43
Asset-Based
NCAV (Graham) 0.0200 MYR 0.0300 MYR 0.0500 MYR 50
Growth DCF
Growth DCF 0.0100 MYR 0.0100 MYR 0.0200 MYR 80
Economic Profit
Residual Income 0.0300 MYR 0.0200 MYR 0.0100 MYR 76
ROIC Compounder 0.0200 MYR 0.0200 MYR 0.0200 MYR 72
Growth Earnings
Growth-Adj P/E 0.0100 MYR 0.0100 MYR 0.0100 MYR 68

Widest divergence: Multiples (0.0600 MYR) versus Earnings-Based (0.0100 MYR). Highest evidence: Growth DCF (80).

Notify me when 0283 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 90.5M MYR
Revenue growth (YoY) +19.3%
Net margin 1.3%
Return on equity 2.6%
Free cash flow 612K MYR FY2025
Operating margin 4.0%
More key figures
Net debt 3.1M MYR FY2025

Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 49/100

Of which business quality 51 · Market factors (momentum, volatility) 30

Profitability 36
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 47
Earnings quality: real cash, not paper profit
Fin. Strength 42
Balance sheet, leverage, solvency risk
Investment 3
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 24
Price trend over the last 3–12 months (market factor)
52W Momentum 17
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

DC Healthcare Holdings Berhad, an investment holding company, provides aesthetic medical services specializing in non-invasive and minimally invasive procedures in Malaysia.

Full company description

DC Healthcare Holdings Berhad, an investment holding company, provides aesthetic medical services specializing in non-invasive and minimally invasive procedures in Malaysia. The company offers aesthetic services, including facial and skin treatments, facial sculpting, body contouring, and hair growth and removal; and general medical consultation services comprising annual health check-ups and skin disease treatment, as well as sells skincare products to under the newB brand name through online stores. The company was founded in 2016 and is headquartered in Kuala Puchong, Malaysia. DC Healthcare Holdings Berhad is a subsidiary of DC Healthcare Group Sdn Berhad.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

DC Healthcare Holdings reported revenue of 87.0M MYR in FY2025 versus 25.5M MYR in FY2021, a compound +35.9%/yr. Reported net income was 206K MYR in FY2025, compounding −54.0%/yr from FY2021.

Growth Quality 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
87.0M MYR
Latest YoY
+55.9%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+18.7%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+43.2%
Revenue +35.9%/yr
FY21 25.5M MYR
FY22 52.0M MYR
FY23 67.7M MYR
FY24 55.8M MYR
FY25 87.0M MYR
Net income −54.0%/yr
FY21 4.6M MYR
FY22 9.6M MYR
FY23 2.5M MYR
FY24 −19.6M MYR
FY25 206K MYR

0283 screens 73% overvalued. Compare with HCA Healthcare, Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "DC Healthcare Holdings Fair Value". https://www.fairvalue-calculator.com/stock/0283

Peer Group

Medical Care Facilities · 261 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 49 · Below median
Fair Value upside −73% · Bottom 25%
Return on equity (TTM) 3% · Below median
Return on assets 3% · Below median
Net margin (TTM) 1% · Below median
Operating margin (TTM) 4% · Below median
Revenue growth 19% · Top 25%
Debt / equity 0.20× · Lower than median

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/B 0.54× · Cheaper than 75% of peers
P/S (TTM) 0.27× · Cheaper than 75% of peers
P/FCF 39.9× · Pricier than 75% of peers
EV/EBITDA 2.3× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 23
FUTURE 97 · sector 24
PAST 10 · sector 30
HEALTH 90 · sector 90
DIVIDEND 0 · sector 38

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $378.85 $554.93 +46%
Fresenius SE FRE €41.73 €32.15 -23%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.58 SGD 1.44 SGD -44%
Tenet Healthcare Corporation THC $194.91 $338.05 +73%
Rede D'Or São Luiz S.A RDOR3 R$36.01 R$47.31 +31%
DaVita Inc DVA $231.61 $255.97 +11%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,955 ₹2,955 -67%
Fresenius Medical Care AG FMS $24.68 $45.60 +85%
Aier Eye Hospital Group 300015 ¥8.68 ¥7.67 -12%

Compare DC Healthcare Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is DC Healthcare Holdings (0283) overvalued or undervalued?
As of Jul 12, 2026, our model estimates a fair value of 0.0300 MYR versus a price of 0.1100 MYR, about −73% (overvalued).
What is the fair value of 0283?
Our model-based fair value for DC Healthcare Holdings is 0.0300 MYR (as of Jul 12, 2026), built from audited fundamentals. The current price is 0.1100 MYR.
What is the quality score of 0283?
DC Healthcare Holdings has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of DC Healthcare Holdings (0283)?
DC Healthcare Holdings reported trailing-twelve-month revenue of about 90.5M MYR (latest available figure, as of Jul 12, 2026).
What is the net profit margin of 0283?
The net profit margin of DC Healthcare Holdings is about 1.3%, meaning it keeps roughly 1.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track DC Healthcare Holdings and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.